| Literature DB >> 24430101 |
Rebecca J Tsai, Jennifer Sievert, Joanne Prado, Kaci Buhl, Dave L Stone, Mathias Forrester, Shelia Higgins, Yvette Mitchell, Abby Schwartz, Geoffrey M Calvert.
Abstract
Dichlorvos-impregnated resin strips (DDVP pest strips) are among the few organophosphate products still available for indoor residential use. The residential uses for most other organophosphate products, including most DDVP products, were canceled because they posed unreasonable risks to children. DDVP pest strips act by inhibiting acetylcholinesterase activity in the brain and nerves of insect pests and are designed to gradually release DDVP vapor for up to 4 months. Acute illnesses in humans associated with nonlethal acute exposures usually resolve completely, but recovery is not always rapid. To assess the frequency of acute illnesses associated with DDVP pest strips, cases from 2000 through June 2013 were sought from the 12 states that participate in the Sentinel Event Notification System for Occupational Risks (SENSOR)-Pesticides Program, the National Pesticide Information Center (NPIC), and Health Canada.* A total of 31 acute DDVP pest strip-related illness cases were identified in seven U.S. states and Canada. The majority of these illnesses resulted from use of the product in commonly occupied living areas (e.g., kitchens and bedrooms), in violation of label directions. Although 26 of the 31 cases involved mild health effects of short duration, five persons had moderate health effects. Illnesses caused by excess exposure to DDVP pest strips can be reduced by educating the public about the proper usage of DDVP pest strips and with improvements in label directions.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24430101 PMCID: PMC4584652
Source DB: PubMed Journal: MMWR Morb Mortal Wkly Rep ISSN: 0149-2195 Impact factor: 17.586
Characteristics of patients (N = 31) with acute dichlorvos (DDVP) pest strip–related illness — seven U.S. states and Canada, 2000–2013
| Characteristic | No. | (%) |
|---|---|---|
|
| ||
| ≤19 | 1 | (3) |
| 20–64 | 24 | (77) |
| ≥65 | 4 | (13) |
| Unknown | 2 | (6) |
|
| ||
| Female | 24 | (77) |
| Male | 7 | (23) |
|
| ||
| Neurologic | 21 | (68) |
| Respiratory | 17 | (55) |
| Gastrointestinal | 13 | (42) |
| Other | 11 | (35) |
| Skin | 7 | (23) |
| Eye | 7 | (23) |
|
| ||
| Possible | 30 | (97) |
| Probable | 1 | (3) |
|
| ||
| Low | 26 | (84) |
| Moderate | 5 | (16) |
|
| ||
| Respiratory | 28 | (90) |
| Dermal | 5 | (16) |
|
| ||
| Home | 24 | (77) |
| Workplace (Store/Office) | 3 | (10) |
| Other (Boat/Car) | 3 | (10) |
| Unknown | 1 | (3) |
|
| ||
| Applied DDVP in areas occupied by humans ≥4 hours/day | 18 | (58) |
| Excessive application | 2 | (6) |
| Undetermined | 11 | (35) |
Sum exceeds 100% because some patients had more than one affected body system/organ.
Low severity cases usually resolve without treatment and cause minimal time lost from work (<3 days). Moderate severity cases are not life threatening but require medical treatment and result in <6 days lost from work.
The sum exceeds 100% because two cases had both routes of exposure.
Insufficient data were available to determine whether the DDVP strip usage resulted in a label violation.